Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Balazs Halmos

Showing results (81-90 of 221) with videos related to

Pageof 23
Sort By:
Cancer Letters|October 12, 2016
Mutant allele specific imbalance in oncogenes with copy number alterations: Occurrence, mechanisms, and potential clinical implicationsChih-Chieh Yu, Wanglong Qiu, Caroline S Juang, et al.
Practical Radiation Oncology|October 31, 2020
Who Benefits the Most From Adjuvant Durvalumab After Chemoradiotherapy for Non-small Cell Lung Cancer? An Exploratory AnalysisNitin Ohri, Balazs Halmos, William R Bodner, et al.
Journal of Thoracic Disease|May 13, 2020
Different efficacy in the non-small cell lung cancer patient with bilateral synchronous lesions treated with neoadjuvant gefitinib therapy: a case reportWenxing Du, Yandong Zhao, Yunpeng Xuan, et al.
Carcinogenesis|January 26, 2010
Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cellsZhenfeng Zhang, Susumu Kobayashi, Alain C Borczuk, et al.
Cancers|April 3, 2021
Thyroid Dysfunction in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors (ICIs): Outcomes in a Multiethnic Urban CohortAngelica D'Aiello, Juan Lin, Rasim Gucalp, et al.
Carcinogenesis|January 1, 2013
PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cellsHaiying Cheng, Zhenfeng Zhang, Alain Borczuk, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 20, 2012
Phase-II trial of rebeccamycin analog, a dual topoisomerase-I and -II inhibitor, in relapsed "sensitive" small cell lung cancerAnita Schwandt, Tarek Mekhail, Balazs Halmos, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 22, 2012
Thymidylate synthase expression and molecular alterations in adenosquamous carcinoma of the lungCatherine Shu, Haiying Cheng, Antai Wang, et al.
International Journal of Radiation Oncology, Biology, Physics|June 10, 2026
Long-Term Changes in Physical Activity Among Cancer Survivors After Concurrent Chemoradiotherapy: A Prospective StudyAdel Zakharia, Rafi Kabarriti, William R Bodner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2004
Unusual cases in multiple myeloma and a dramatic response in metastatic lung cancer: case 4. Mutation of the epidermal growth factor receptor in an elderly man with advanced, gefitinib-responsive, non-small-cell lung cancerDaniel Cho, Olivier Kocher, Jeffrey C Lee, et al.
Pageof 23

Showing results (81-90 of 221) with videos related to

Sort By:
Pageof 23
Cancer Letters|October 12, 2016
Mutant allele specific imbalance in oncogenes with copy number alterations: Occurrence, mechanisms, and potential clinical implicationsChih-Chieh Yu, Wanglong Qiu, Caroline S Juang, et al.
Practical Radiation Oncology|October 31, 2020
Who Benefits the Most From Adjuvant Durvalumab After Chemoradiotherapy for Non-small Cell Lung Cancer? An Exploratory AnalysisNitin Ohri, Balazs Halmos, William R Bodner, et al.
Journal of Thoracic Disease|May 13, 2020
Different efficacy in the non-small cell lung cancer patient with bilateral synchronous lesions treated with neoadjuvant gefitinib therapy: a case reportWenxing Du, Yandong Zhao, Yunpeng Xuan, et al.
Carcinogenesis|January 26, 2010
Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cellsZhenfeng Zhang, Susumu Kobayashi, Alain C Borczuk, et al.
Cancers|April 3, 2021
Thyroid Dysfunction in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors (ICIs): Outcomes in a Multiethnic Urban CohortAngelica D'Aiello, Juan Lin, Rasim Gucalp, et al.
Carcinogenesis|January 1, 2013
PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cellsHaiying Cheng, Zhenfeng Zhang, Alain Borczuk, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 20, 2012
Phase-II trial of rebeccamycin analog, a dual topoisomerase-I and -II inhibitor, in relapsed "sensitive" small cell lung cancerAnita Schwandt, Tarek Mekhail, Balazs Halmos, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 22, 2012
Thymidylate synthase expression and molecular alterations in adenosquamous carcinoma of the lungCatherine Shu, Haiying Cheng, Antai Wang, et al.
International Journal of Radiation Oncology, Biology, Physics|June 10, 2026
Long-Term Changes in Physical Activity Among Cancer Survivors After Concurrent Chemoradiotherapy: A Prospective StudyAdel Zakharia, Rafi Kabarriti, William R Bodner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2004
Unusual cases in multiple myeloma and a dramatic response in metastatic lung cancer: case 4. Mutation of the epidermal growth factor receptor in an elderly man with advanced, gefitinib-responsive, non-small-cell lung cancerDaniel Cho, Olivier Kocher, Jeffrey C Lee, et al.
Pageof 23